Lung cancer is divided into non-small-cell lung carcinoma (NSCLC) and small-cell lung carcinoma, with NSCLC accounting for the most of all of cases (approximately 85%). According to 2015 statistics, there were approximately 730,000 new cases of lung cancer in China and more than 430,000 people died from this disease. Lung cancer is one of the leading causes of cancer related mortality worldwide, as well as in China. We also identified new prognostic biomarkers, which could provide potential clues for targeted therapies. Our study provided comprehensive genomic alterations in a cohort of Chinese NSCLC. In the patients received targeted therapy, adenocarcinoma patients had a significantly longer survival period than squamous patients ( P = 0.01). In the patients received chemotherapy, squamous patients had a significantly longer median OS than adenocarcinoma patients ( P = 0.011). Using a multivariate Cox regression model, PREX2 ( P < 0.001), ARID1A ( P < 0.001) and PIK3CG ( P = 0.04) were independent prognostic factors in NSCLC.
Patients with mutant TP53, PREX2, ARID1A, PTPRT and PIK3CG had lower median overall survival (OS) than those patients with wild-type ( P = 0.0056, P < 0.001, P < 0.0001, P < 0.0001 and P = 0.036, respectively). ResultsĪ total of 899 mutations were identified by targeted NGS. The associations between clinical outcomes and clinical characteristics, TMB, mutated genes, treatment therapies were analyzed using Kaplan-Meier methods and further evaluated using multivariable Cox proportional hazards regression model. Tumor tissues or blood were collected and sequenced by targeted next-generation sequencing of 556 cancer related genes. PatientsĪ total of 117 Chinese patients with NSCLC were enrolled in this study. No cash balance or cash flow is included in the calculation.Comprehensive information about the genome analysis and its prognostic values of NSCLC patients in Chinese population are still needed. Please note all regulatory considerations regarding the presentation of fees must be taken into account. Backtested results are adjusted to reflect the reinvestment of dividends and other income and, except where otherwise indicated, are presented gross-of fees and do not include the effect of backtested transaction costs, management fees, performance fees or expenses, if applicable. Actual performance may differ significantly from backtested performance. Further, backtesting allows the security selection methodology to be adjusted until past returns are maximized. Since trades have not actually been executed, results may have under- or over-compensated for the impact, if any, of certain market factors, such as lack of liquidity, and may not reflect the impact that certain economic or market factors may have had on the decision-making process.
Specifically, backtested results do not reflect actual trading or the effect of material economic and market factors on the decision-making process. Backtested performance is developed with the benefit of hindsight and has inherent limitations. This information is provided for illustrative purposes only. No representations and warranties are made as to the reasonableness of the assumptions. Certain assumptions have been made for modeling purposes and are unlikely to be realized. Changes in these assumptions may have a material impact on the backtested returns presented. General assumptions include: XYZ firm would have been able to purchase the securities recommended by the model and the markets were sufficiently liquid to permit all trading. Backtested results are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained.
Backtested performance is not an indicator of future actual results. Disclaimer: The TipRanks Smart Score performance is based on backtested results.
0 kommentar(er)
